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Abstract Type 2 diabetes mellitus (T2DM) is associated with
cognitive dysfunction. Previous studies have reported the re-
lationship between cerebral metabolite changes and glucose
levels. However, the specific aspects of cognition that are
affected by metabolic changes in T2DM- related cognitive
impairment remain undetermined. In this study, 188 T2DM
patients and 266 controls were recruited. Proton magnetic res-
onance spectra with a single voxel stimulated echo acquisition
mode (STEAM) were acquired from the left hippocampus and
the frontal lobe. Presence of T2DM negatively affected the
scores of Mini-Mental State Examination (MMSE), sub-tests
(i.e., attention and language) of MMSE, Montreal Cognitive
Assessment (MoCA) according to the Beijing version, and
sub-tests (i.e., visuospatial/executive reasoning, attention,
and language) of MoCA, rather than the Wechsler Memory
Scale – Revised in China (WMS-RC), and all memory sub-
tests contained with the MMSE and MoCA frameworks.
T2DMpositively affected creatine and myoinositol peak areas
from the left hippocampus, rather than metabolites in the left
frontal lobe. Negative correlations were shown between the
left hippocampal myoinositol levels and language scores, and
between the left hippocampal creatine levels and visuospatial/
executive scores in T2DM. These findings suggest that T2DM
may be an independent risk factor for cognitive impairment.
Further, the cognitive domains of visuospatial /executive rea-
soning, attention and language may be predominantly im-
paired in the early phases of T2DM-related cognitive impair-
ment. In addition, left hippocampal myoinositol and creatine
concentrations were associated with cognitive impairment in
patients with T2DM.
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Introduction
Type 2 diabetes mellitus (T2DM) is associated with cognitive
dysfunction and an increased risk of dementia. There is still
uncertainty with regard the etiology, but vascular disease is
likely to play a role (Biessels et al. 2008). There is growing
interest in potential correlations between cognitive function
and changes in cerebral metabolites in T2DM, since this dis-
ease presentation is a metabolic disorder.
At present, magnetic resonance spectroscopy (MRS) is the
only available non-invasive method for detecting biochemical
molecules within living organs (Vrenken et al. 2005). Recent
studies have used MRS to reveal the relationship between
changes in brain neurochemistry and glucose levels, such as
decreased N-acetyl-aspartate (NAA)/creatine (Cr) ratios in the
pons, and the left posterior parietal white matter of poorly con-
trolled type 1 diabetes mellitus in children (Sarac et al. 2005)
and in the frontal cortex of patients that presented with T2DM
with higher glycosylated hemoglobin A1c (HbA1c) levels
(>10 %) (Sahin et al. 2008). MRS has also been used to show
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increased myoinositol (mI) levels in the occipitoparietal grey
matter of patients that presented with metabolic syndrome and
normal cognition (Haley et al. 2010), and in cases of increased
Cr in the thalamus of participants at risk of developing meta-
bolic syndrome (Heikkilä et al. 2008), and in cases of increased
choline-containing compounds (Cho)/Cr ratios in the left oc-
cipital lobe of T2DM patients (Modi et al. 2008). Other studies
have used MRS to reveal the relationship between changes in
neurochemistry and cognitive impairment. It was revealed that
mI was increased and NAA was decreased in the occipital,
parietal (Huang et al. 2001), and hippocampus (Watanabe
et al. 2012) of Alzheimer’s disease patients. However, these
studies did not investigate the specific aspects of cognition that
reflected these metabolic changes in T2DM-related cognitive
impairment.
In this study, we used neuropsychological scales and MRS
in patients with T2DM to investigate the cognitive changes
and neurochemical abnormalities in the left hippocampus and
the left frontal lobe, which are both closely related to cognition
in right-handed people, especially in the context of language
message retention and memory, and executive reasoning pro-
cesses (Smith and Jonides 1999; Schaefer et al. 2006;
Watanabe et al. 2012; Jefferies 2013) that conform to neuro-
psychological scales. We evaluated the correlations between
neuropsychological scales and levels of specific metabolites.
Methods
Participants
All participants were recruited consecutively at the out-patient
department of endocrinology and neurology of Shanghai East
Hospital affiliated to Tongji University between September
2009 and February 2014. Recruited patients underwent com-
prehensive diagnostic evaluation, including demographic pa-
rameters such as age, gender, educational status, body mass
index (BMI), personal histories of hypertension, presence of
T2DM, cardiovascular disease, presence of hyperlipidemia,
and lifestyle risk factors including smoking habits, neurolog-
ical and psychiatric examinations, neuropsychological testing,
basic laboratory tests, and clinical laboratory findings such as
fasting blood glucose levels, glycosylated hemoglobin A1c
(HbA1c) and brain magnetic resonance imaging (MRI).
Inclusion criteria of the T2DM group included: (1) T2DM
that was diagnosed in accordance with the diagnostic criteria
of the American Diabetes Association, 1997, (2) timespan of
T2DM of 3–10 years, (3) right handedness, (4) urine ketone
negative, and (5) an Activity of Daily Living scale (ADL)
score≤16, a Global Deterioration Scale (GDS) score ≤3, and
a Hamilton Depression scale (HAMD) score ≤7. Inclusion
criteria of the control group included: (1) non-T2DM, (2) right
handedness, and (3) an ADL score≤16, a GDS score ≤3, and
an HAMD score ≤7. The exclusion criteria were medical his-
tories of stroke or other major neurological disease or condi-
tion, evidence of psychiatric disorders (e.g., schizophrenia,
and bipolar disorder, etc.), substance abuse (e.g., alcohol,
drugs, or other), and metabolic encephalopathy (e.g., hepatic
encephalopathy, and pulmonary encephalopathy).
The protocol was approved by the local ethics committees
of the Shanghai East Hospital Affiliated to Tongji University
and the study was operated in accordance with the World
Medical Association’s Declaration of Helsinki. All of the par-
ticipants provided written and informed consent before enroll-
ment. In total, 188 patients that had presented with T2DM and
266 participants with non-T2DM were recruited to this study.




Fasting blood concentrations of glucose, HbA1c, routine uri-
nalysis, total triglycerides, total cholesterol, high density lipo-
protein (HDL)-cholesterol levels, and low density lipoprotein
(LDL)-cholesterol levels were detected by standard enzymatic
assays. Radial artery blood pressure was measured by a stan-
dard blood pressure monitor (VP-2000, Colin Medical
Technology Corporation, Japan) after at least 10 min of whole
body rest.
Neuropsychological evaluation
Cognitive assessments included the Mini-mental State
Examination (MMSE), Montreal Cognitive Assessment
(MoCA) – Beijing version, and Wechsler Memory Scale -
Revised in China (WMS-RC) (Gong. 1989). Cognitive eval-
uation and blood biochemical measurements were also per-
formed on the same day. The participants were not fasting
during the cognitive evaluation.
The MMSE consisted of orientation, immediate memory,
attention, delayed memory, language (i.e., naming, repeating,
auditory comprehension, reading, and writing skills), and
visual-spatial ability, for a maximum total score of 30. The
MoCA tests included analysis of visuospatial/executive rea-
soning, naming, attention, memory, language, abstraction, and
orientation skills, which were aggregated for a maximum
score of 30. WMS-RC tests included long-term memory
(i.e., personal experience, orientation, and digit order), short-
term memory (i.e., visual recognition, visual reproduction,
picture recollection, associative learning skills, touch test,
and comprehension memory skill), and immediate-termmem-
ory (i.e., digit span). A normal range for the memory quotient
(MQ) is 90–109.
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All 454 participants were assessed by MMSE and MoCA,
and among them 98 participants were assessed by WMS-RC.
All tests were administered and scored by a professionally
trained operator in neuropsychometric testing.
MRI and 1H-MRS
Both MRI and proton magnetic resonance spectroscopy (1H-
MRS) were performed on a 3.0 Tesla apparatus (Philips Intera
Achieva, Netherlands) using a standard head coil suited for
MRI andMRS. The protocol for structuralMRI included axial
T2 weight imaging (T2WI), sagittal T2WI, and hippocampal
oblique coronal T2WI with repetition time (TR)/echo time
(TE)=5500/130 with a slice thickness of 6 mm and a gap of
1 mm.
In order to measure the mI concentrations as a mea-
sure of the metabolism of short T2, and to improve the
sensitivity and resolution, we chose stimulated echo ac-
quisition mode (STEAM) analysis on a 3.0 Tesla appa-
ratus. 1H-MRS parameters were as follows: TE=9.4 ms,
TR=2000 ms, 128 excitations, acquire time (TA)=4 min
48 s, a volume of 10 mm3 from the left hippocampus
and 20 mm3 from the left frontal lobe (Fig. 1). The
chosen volumes covered the region of interest (ROI)
as completely as possible without including the cerebral
spinal fluid (CSF) or other regions. Smaller regions than
those shown above, would have caused deviations due
to the slight movement that occurs with breathing and
regular heartbeats.
Cerebral structural changes such as lacunar cerebral
infarction, leukoaraiosis, and encephalatrophy were ob-
served visually and classified as yes or no. Spectral
peak areas corresponding to the metabolites NAA
(2.0 ppm), Cho (3.2 ppm), Cr (3.02 ppm), and mI
(3.56 ppm) were quantified in the frequency domain,
fitting for frequencies, and areas and line widths with
a Gaussian line shape using in-house software. All im-
ages were acquired by a professional radiology techni-
cian, which was conducted in a double-blind data acqui-
sition method. The participants were not fasting during
the 1H-MRS procedure. Further, the interval between
cognitive evaluation and imaging was less than three
days. The tests performed were conducted in the same
sequence for all participants.
Statistical analyses
Data were analyzed using the Statistical Package for
Social Sciences (SPSS version 17.0; SPSS, Chicago, IL,
USA). All comparisons of the demographic data were
performed by t tests and χ2 tests. Multiple liner regres-
sion analyses calculated the associations of the neuropsy-
chological scales and the variables of metabolite
concentrations found in patients presenting with T2DM.
Partial correlation coefficients were calculated to reveal
associations between the variables of metabolite concen-
trations and neuropsychological scales. All values de-
scribed in the text and tables were mean and standard
deviation unless stated otherwise. A two-tailed alpha lev-
el of P<0.05 was the criterion for statistical significance.
Results
Demographics
A total of 454 participants were in the final sample analysis, of
which 188 patients were in the T2DM patient group and 266
were in the control group. The duration of diabetes was cal-
culated as 76.16±37.98 months in the T2DM group. The de-
mographic details and clinical characteristics of the subjects
are summarized in Table 1.
Cognitive function and metabolite concentrations
The t-tests showed that the T2DM group had signifi-
cantly lower scores for MMSE and MoCA than did
the control group (all p<0.05). However, there were
no significant differences in MQ scores between groups
(Table 1). Multiple liner regression analyses, using the
scores of MMSE, sub-tests of MMSE, MoCA, and sub-
tests of MoCA as dependent variables and age, gender,
educational status, smoking habits, BMI, presence of
T2DM, hypertension, cardiovascular disease, hyperlipid-
emia, and cerebral structural changes as independent
variables in all participants, evaluated the associations.
Tables 2–3 showed that T2DM negatively affected the
scores of MMSE, the sub-tests (i.e., attention and lan-
guage) of MMSE, MoCA, and sub-tests (i.e., visuospatial/
executive reasoning, attention, and language skills) of MoCA
(all p<0.05). T2DM did not significantly affect all memory
subtests of MMSE and MoCA.
Using 1H-MRS, the absolute concentrations of NAA,
Cho, Cr, and mI in the left hippocampus and left frontal
lobe were obtained. Multiple linear regression analyses
that used the absolute concentrations of NAA, Cho, Cr,
and mI in the left hippocampus and left frontal lobe as
dependent variables, and age, gender, smoking habits,
BMI, T2DM, hypertension, cardiovascular disease, hy-
perlipidemia, and cerebral structural changes as indepen-
dent variables in all participants, were employed to
evaluate the putative associations. Table 4 showed that
T2DM positively affected the concentrations of Cr and
mI in the left hippocampus (all p<0.05). Further, T2DM
did not significantly affect the left frontal lobe NAA,
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Cho, Cr, and mI levels and the left hippocampal NAA
and Cho levels.
Correlation of the left hippocampal Cr and mI
concentrations with neuropsychological scales
Partial correlation coefficients were calculated to reveal
the correlations of the left hippocampal Cr and mI con-
centrations with the following: the psychological scales,
adjusted age, gender, educational status, smoking habits,
BMI, HbA1c, hypertension, cardiovascular disease,
hyperlipidemia, changes in cerebral structure, and other
metabolic concentrations in the left frontal lobe and left
hippocampus. Table 5 showed that there was a signifi-
cant negative correlation between the levels of left hip-
pocampal mI and the language scores of MoCA in pa-
tients that presented with T2DM. There was also a sig-
nificant negative correlation between the left hippocam-
pal Cr concentration and the visuospatial/executive
scores of MoCA in patients that had presented with
T2DM. Table 5 also showed that there were no signif-
icant correlations between the left hippocampal Cr and
Fig. 1 The region of interest:
volume 20 mm3 from the left
frontal lobe (a) and volume
10 mm3 from the left
hippocampus (b), and a left
hippocampal spectrum of a
participant with type 2 diabetes
mellitus (c)
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Table 1 Demographics and
clinical characteristics in T2DM
group and control group
T2DM group Control group p
Gender Men (n) 95 128 0.64
Women (n) 93 138
Age (year) 60.97±9.05 60.50±10.85 0.59
Educational status (year) 9.32±3.80 10.18±3.95 0.02
Fasting blood glucose(mmol/L) 8.65±4.01 4.99±0.65 <0.001
HbA1c (%) 8.45±2.19 5.70±0.29 <0.001
Hypertension (n) 134(71.28 %) 124(46.62 %) <0.001
Systolic pressure(mmHg) 136.76±11.15 130.17±10.58 <0.001
Diastolic pressure(mmHg) 87.02±6.04 84.13±4.90 <0.001
Hyperlipidemia (n) 53(28.19 %) 52(19.55 %) 0.04
Cholesterol(mmol/L) 4.76±1.13 4.82±1.07 0.66
Triglycerides(mmol/L) 2.05±1.74 1.61±1.10 0.02
HDL(mmol/L) 1.18±0.35 1.35±0.49 0.001
LDL(mmol/L) 3.00±0.88 3.07±0.98 0.52
Cardiovascular disease (n) 60(31.91 %) 56(21.05 %) 0.01
Smoking habits (n) 72(38.30 %) 72(27.07 %) 0.01
BMI 24.40±2.74 23.19±3.01 <0.001
Cerebral structural changes (n) 156(82.98 %) 209(78.57 %) 0.28
MMSE 25.09±4.29 26.06±3.81 0.01
MoCA 18.81±5.63 20.76±5.02 <0.001
Memory quotient 78.24±21.92 88.50±18.76 0.08
Left hippocampus NAA 0.072±0.088 0.064±0.079 0.15
Cr 0.066±0.076 0.049±0.053 0.01
Cho 0.055±0.091 0.053±0.055 0.18
mI 0.064±0.071 0.044±0.058 0.02
Left frontal lobe NAA 0.348±0.350 0.353±0.365 0.51
Cr 0.234±0.239 0.237±0.265 0.41
Cho 0.206±0.201 0.199±0.268 0.41
mI 0.136±0.167 0.127±0.266 0.33
Table 2 Multiple linear regression analyses of MMSE, subtests of MMSE, and interference factors for cognitive changes in all participants







Constant 24.567 9.176 2.780 4.944 2.337 4.796 0.564
Gender 0.524 0.071 0.044 −0.102 0.095 0.334a 0.063
Age −0.093b −0.023b −0.006a −0.020b −0.026b −0.011 −0.006a
Educational status 0.426b 0.071b 0.028b 0.070b 0.051b 0.168b 0.040b
Hypertension 0.738a 0.162 0.066 0.178 0.143 0.230a 0.031
Hyperlipidemia −0.220 0.208 0.025 −0.237 −0.107 −0.121 0.027
Cardiovascular disease 0.271 −0.009 −0.045 0.189 0.062 0.182 −0.041
Smoking habits 0.497 0.066 −0.011 0.105 −0.031 0.298a 0.101
Cerebral structural changes −0.700 −0.113 −0.003 −0.377a −0.028 −0.271 −0.007
BMI 0.089 0.026 0.003 0.001 0.021 0.030 0.003
T2DM −0.784a −0.098 −0.009 −0.257a −0.007 −0.328b −0.071
a p<0.05
b p<0.01
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the mI concentrations and neuropsychological scales in
the control group.
Discussion
Clinically, individuals that present with T2DM commonly
have a cluster of accompanying interrelated metabolic dis-
eases including hypertension, cardiovascular disease, hyper-
lipidemia, and cerebral structural changes like leukoaraiosis
(Bastos-Leite et al. 2008; van Harten et al. 2006), cortical and
subcortical atrophy (Musen et al. 2006; Wessels et al. 2006),
which have all been linked to cognitive decline (Gatto et al.
2008; Yaffe et al. 2009). In this study, we adjusted the multiple
interfering factors of cognitive changes in an attempt to ob-
serve T2DM-related cognitive impairment in the clinical
setting.
We found that T2DM negatively affected the scores of
MMSE, MoCA, sub-tests (attention and language skills) of
MMSE, and sub-tests (i.e., visuospatial/executive, attention,
and language skills) of MoCA, rather than the scores of MQ
and all memory sub-tests of MMSE and MoCA. These results
suggested that T2DM-related cognitive impairment occurred
in our study, and were early cognitive impairments, in part
Table 3 Multiple linear regression analyses of MoCA, subtests of MoCA, and interference factors for cognitive changes in all participants
MoCA Subtests of MoCA
Visuospatial/
executive
Naming Attention Language Abstraction Memory Orientation
Constant 21.612 2.879 1.284 4.918 0.727 0.352 2.958 6.478
Gender 0.195 −0.027 −0.241a 0.027 0.179 −0.079 0.405a 0.042
Age −0.165b −0.023b −0.006 −0.025b −0.016b −0.010a −0.056b −0.017b
Educational status 0.600b 0.145b 0.087b 0.129b 0.073b 0.072b 0.109b 0.036b
Hypertension 0.536 0.075 −0.063 0.145 0.063 −0.008 0.266 0.098
Hyperlipidemia −0.114 −0.049 0.071 −0.097 −0.023 −0.007 −0.213 0.154
Cardiovascular disease 0.636 0.242 0.143 0.219 0.064 0.013 −0.058 0.001
Smoking habits 0.374 0.184 0.167 0.039 0.087 −0.022 −0.111 0.055
Cerebral structural changes −1.250a −0.374a −0.089 −0.407b −0.132 −0.015 −0.349 −0.126
BMI 0.132 0.017 0.027 0.015 0.036b 0.019 0.038 −0.014
T2DM −1.629b −0.397b −0.005 −0.335b −0.302b −0.146 −0.235 −0.108
a p<0.05
b p<0.01
Table 4 Multiple linear regression analyses of brain metabolites in the left hippocampus and left frontal lobe, and interference factors for metabolite
changes in all participants
Left hippocampus Left frontal lobe
NAA Cr mI Cho NAA Cr mI Cho
Constant 0.182 0.046 0.154 0.170 0.276 −0.074 −0.594 4.801
Gender 0.027 0.077 0.034 0.199 −0.022 0.025 0.026 0.422
Age −0.002 −0.001 −0.002 −0.002 0.005 0.004 0.011 −0.049
Hypertension −0.022 −0.085 −0.062b −0.188 0.009 0.057 0.170 0.946
Hyperlipidemia 0.020 0.059 0.011 0.232a −0.060 −0.057 −0.184 −0.495
Cardiovascular disease 0.023 0.120b 0.080b 0.246a −0.110 −0.098 −0.286 −0.303
Smoking habits 0.011 0.081 0.029 0.045 −0.007 0.002 0.282 −0.159
Cerebral structural changes −0.063a −0.007 0.027 −0.046 −0.061 0.035 0.017 0.865
BMI −0.004 −0.002 −0.003 −0.010 0.000 0.004 0.010 −0.111
T2DM 0.042 0.153b 0.057b 0.166 −0.031 −0.039 −0.206 −0.436
a p<0.05
b p<0.01
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because one of the inclusion criteria was an ADL score≤16,
an HAMD score ≤7, and a GDS score ≤3. Thus, T2DMmight
be an independent risk factor for cognitive impairment, and
the cognitive domains of visuospatial/ executive reasoning,
and attention and language skills might be predominantly im-
paired in the early phases of T2DM-related cognitive impair-
ment, rather than the cognitive function of memory.
NAA has been proposed as a marker of neuronal density
and viability (Moffett et al. 2007), Cho is involved in mem-
brane breakdown (Gujar et al. 2005), Cr is involved in energy
metabolism, and increased Cr has previously been shown to
be related to increased oxidative metabolism in both neurons
and glial cells (Ross and Bluml 2001), and mI has been
interpreted as a marker of gliosis, an organic osmolyte and a
precursor in the synthesis of the second messenger inositol tri-
phosphate (Fisher et al. 2002).
T2DM positively affected the levels of Cr and mI in the left
hippocampus, and there was no significant relationship be-
tween T2DM and the left hippocampal NAA and Cho in this
study, which suggested that neuronal density was unchanged,
glial cell membrane turnover was intact and the left hippocam-
pal Cr and mI levels were increased in T2DM. An animal
study showed that the concentrations of mI and Cr in the
hippocampus of Zucker Diabetic Fatty rats were increased
(van der Graaf et al. 2004). In addition, insulin receptors in
the hippocampal neurons are highly concentrated (Park 2001),
suggesting that the synthesis of energy in the hippocampus
may be abnormal, resulting from insulin resistance due to
the glucose metabolism disorder that characterizes T2DM.
The increased Cr may therefore indicate an increased need
for an energy buffering capacity in the left hippocampus in
the setting of T2DM. In addition, elevated left hippocampal
mI in T2DMmay be interpreted as a sign of gliosis, which we
have previously reported (Li et al. 2011), and disturbance in
intracellular second messenger transmission, caused by insu-
lin resistance in T2DM.
Our study also showed that left hippocampal mI concen-
trations were negatively correlated with language scores and
the left hippocampal Cr concentrations were negatively corre-
lated with visuospatial/executive reasoning scores in T2DM.
There were strong correlations between the mI concentrations
and the number of neuritic plaques and neurofibrillary tangles
in patients with Alzheimer’s disease (Ross and Sachdev.
2004). In addition, elevated concentrations of mI have been
reported in the bilateral hippocampi of Alzheimer’s disease
patients. Furthermore, left hippocampal mI concentrations
were associated with cognitive dysfunction commonly ob-
served in patients with Alzheimer’s disease (Watanabe et al.
2012). Our results suggested that left hippocampal myoinosi-
tol and creatine levels were associated with cognitive impair-
ment in T2DM patients.
In the present study, no significant relationships were found
between any metabolite level in the left frontal lobe and
T2DM. A similar result was found by Modi et al. (2008)
who reported that Cho/Cr and NAA/Cr ratios showed no dif-
ferences in the left frontal white matter when comparing
T2DM patients and normal controls. In this study, T2DM
affected changes in metabolites in the left hippocampus rather
than the left frontal lobe, which might suggest that metabolite
changes were not the same in different cerebral regions of
subjects that presented with T2DMwith a duration that ranged
from 3 to 10 years. The key reason for this is that the subjects
that were studied in this article had undergone glycemic
control.
Though the present study is limited by multiple interfer-
ence factors of changes in neuro- cognitive function, the re-
sults clearly gave insights into the metabolite changes that
were associated with T2DM-related cognitive impairment.
Further studies are needed to demonstrate whether or not dif-
ferential medical therapies affect the metabolic changes that
are associated with T2DM-related cognitive impairment.
In conclusion,T2DM might be an independent risk factor
for cognitive impairment, and might lead to changes in left
hippocampal metabolism. Cognitive domains of visuospatial /
executive, and attention and language skills might be predom-
inantly impaired in early T2DM-related cognitive impairment.
Increased left hippocampal myoinositol and creatine levels
that were measured by 1H-MRS might reflect cognitive im-
pairment in T2DM patients.
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T2DM group Control group
mI Cr mI Cr
MoCA 0.058 −0.118 0.089 0.070
Visuospatial/
executive
0.184 −0.233a 0.036 0.066
Attention −0.008 0.134 0.090 −0.079
Language −0.233a 0.152 0.091 0.008
MMSE 0.040 0.074 0.078 −0.003
Attention 0.011 0.227 0.028 0.094
Language 0.037 −0.059 0.090 −0.131
a p<0.05
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